Camsing Healthcare (BAC) Q1 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 TU earnings summary
29 Oct, 2026Executive summary
Q1FY2026 revenue rose 17% YoY to S$1.251m, while the net loss narrowed to S$480k from S$669k; the Group remained in a net-liability position of S$4.319m.
Management is reorganizing the retail portfolio, closing loss-making outlets and expanding online sales; performance improvement is expected barring unforeseen circumstances.
Financial highlights
Revenue was S$1.251m, up 17% YoY; cost of sales rose 52% to S$607k and gross profit fell 4% to S$644k.
Other income was S$61k versus S$50k; marketing and distribution costs fell 10% to S$844k, while administrative and other operating expenses rose 6% to S$321k.
Loss before tax and net loss were S$480k, versus S$669k in Q1FY2025; lower marketing costs and finance costs partly offset higher administrative expenses.
Operating cash outflow was S$200k versus S$72k; financing generated S$123k and period-end cash was S$51k.
Outlook and guidance
Plans include developing new products, expanding sales channels and applying prudent cost management; online sales and collaborations with e-commerce operators are expected to support volume.
Management is closing loss-making outlets and expanding online presence, and is cautiously optimistic about improved performance barring unforeseen circumstances.
Latest events from Camsing Healthcare
- Revenue grew 9%, but losses widened amid financing pressure and going-concern uncertainty.BAC
Q1 2024 TU - Higher gross margin and positive operating cash flow were not enough to offset ongoing losses and funding uncertainty.BAC
Q3 2024 TU - Sales fell 26% as quarterly loss widened to S$669k amid acute liquidity risk.BAC
Q1 2025 TU - Loss narrowed, but weak demand and tight liquidity leave material going-concern risk.BAC
Q3 2025 TU - Revenue fell 16%, losses narrowed, but liquidity and going-concern risks persist.BAC
Q3 2026 TU - Revenue fell 30% YoY; losses narrowed, but going-concern uncertainty remains.BAC
Q1 2027 TU - Narrower losses, but weak cash flow, material audit concerns and major outlet restructuring.BAC
H2 2025 - Revenue fell, losses widened, and liquidity hinges on trading resumption and investor funds.BAC
H2 2024 - Losses narrowed, but severe liquidity pressure and going-concern uncertainty persist.BAC
H2 2026